Carey Thomas D. 4

What Happened
Thomas D. Carey, a director of Standard BioTools, was granted 51,282 restricted stock units (RSUs) on 2026-02-26 at an implicit price of $1.17 per share, with a total value of $60,000. This was an award (transaction code A) issued in lieu of cash compensation for board services, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-26; reported on Form 4 filed 2026-03-02 (filed within the SEC’s two-business-day window).
• Security: 51,282 RSUs; grant value = $60,000; per-share implied value reported = $1.17.
• Shares owned after transaction: not specified in the provided filing.
• Footnotes:
  • F1: RSUs vest 25% on the last day of the last month of each fiscal quarter of 2026, subject to continued service.
  • F2: RSUs were issued because Carey elected to receive RSUs instead of $60,000 cash board compensation.
• Transaction type: Award/acquisition (A) — compensation, not a market trade.

Context
RSU grants are compensation and typically reflect pay arrangements rather than a direct sentiment signal; the units vest over four quarterly installments in 2026 if Carey remains in service. Because these shares were issued in lieu of cash, they don’t indicate a purchase financed by the director’s conviction in the stock; they simply convert cash pay into equity.